AI-generated illustration. Visual interpretation does not represent real individuals or scenes.
FDA Replaces Top Regulators Following Commissioner's Resignation
2026-05-16
The BareStory
The U.S. Food and Drug Administration is replacing the acting directors of its primary drug and biologics evaluation centers. The leadership changes follow a broader personnel shake-up at the agency, which includes the recent resignation of FDA Commissioner Dr. Marty Makary.
Dr. Tracy Beth Høeg is leaving her position as acting director of the Center for Drug Evaluation and Research, and Katherine Szarama is stepping down as acting director of the Center for Biologics Evaluation and Research. Høeg claimed in a social media post that she was fired from her role. An agency memo indicated that Szarama will remain at the FDA in another capacity. According to an updated organizational chart, Michael Davis will succeed Høeg, Karim Mikhail will replace Szarama, and Lowell Zeta will become the acting chief of staff.
The division transitions occurred days after Commissioner Makary resigned. A source familiar with the matter alleged that Makary departed due to a dispute over the approval of flavored e-cigarettes, amid broader reports of internal agency tensions and executive pressure. The FDA has experienced multiple high-level turnover events over the past year, including the recent exit of Dr. Vinay Prasad, the former head of vaccine approvals.
A senior administration official stated that the Trump administration intends to name a nominee for a permanent FDA commissioner in the coming weeks. The position will require Senate confirmation.
Left Perspective
Shield Against Political Coercion
Dismantling Institutional Expertise
Gamble on Regulatory Capture
Right Perspective
Mandate for Executive Alignment
Breaking Bureaucratic Inertia
Pivot to Constitutional Process
Left Perspective
• Shield Against Political Coercion
Prioritizes the protection of vulnerable populations by maintaining strict boundaries between public health decisions and political influence. Views the reported executive pressure on Commissioner Makary to approve flavored e-cigarettes as a dangerous prioritization of commercial interests over citizen well-being. This camp perceives his resignation not as an administrative shift, but as a severe failure of government accountability where independent science is subordinated to political dictates.
• Dismantling Institutional Expertise
Values the preservation of rigorous, evidence-based systems designed to safeguard public safety and maintain civil stability. Interprets the firing of CDER acting director Tracy Beth Høeg and the reassignment of CBER acting director Katherine Szarama—following the recent exit of vaccine head Vinay Prasad—as a targeted purge of technical expertise. This systemic removal of specialized directors is seen as a reckless disruption of the institutional status quo that keeps the public safe.
• Gamble on Regulatory Capture
Fears that replacing independent regulators with rapidly appointed, politically aligned successors fundamentally compromises the agency’s consumer protection mandate. By abruptly installing Michael Davis, Karim Mikhail, and Lowell Zeta amidst broader internal tensions, this side anticipates a long-term erosion of objective safety standards. The overriding concern is that without insulated scientific leadership, the FDA will lose its ability to hold industries accountable.
Right Perspective
• Mandate for Executive Alignment
Prioritizes the democratic chain of command, asserting that federal agencies must faithfully execute the policy vision of the elected administration. Views the replacement of acting directors under the Trump administration as a necessary and lawful exercise of executive authority. Removing officials who clash with the overarching policy agenda ensures the agency operates as a cohesive arm of the government rather than an autonomous, unaccountable entity.
• Breaking Bureaucratic Inertia
Values institutional order and efficiency over the preservation of entrenched administrative holdovers. Interprets Commissioner Makary’s resignation over the flavored e-cigarette dispute as a necessary clearing of internal bottlenecks caused by unelected regulators obstructing clear executive directives. By decisively rotating leadership in the drug and biologics centers, this camp sees a vital restoration of operational discipline and clear hierarchical authority.
• Pivot to Constitutional Process
Emphasizes the importance of formal, legally mandated structures over reliance on a fractured patchwork of temporary acting directors. Views the installation of interim leaders like Davis and Mikhail as a necessary, stabilizing bridge toward the administration’s impending nomination of a permanent commissioner. This trajectory is championed as a return to systemic stability, ensuring the agency is led by an official who will face formal Senate vetting to reinforce civic duty.
How it may affect me
As a U.S. reader:
• In the short term, consumers may see shifts in the approval and availability of flavored e-cigarettes, as disagreements and executive directives regarding these products directly contributed to the recent resignation of the FDA commissioner.
• Leadership transitions within the drug, biologics, and vaccine evaluation centers could alter the processes, speed, and safety standards used to review and approve new medical treatments.
• Over the long term, industry oversight and consumer protections may change as the agency shifts away from autonomous regulatory models toward closer alignment with the policy goals of the elected administration.
• The future direction and stability of national public health guidelines will likely be formalized in the coming weeks when a permanent FDA commissioner is nominated and undergoes the Senate confirmation process.
